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Private sphereDue to the few patients affected, rare disease research has to count on international registries to exist in order to
produce signiﬁcant research outputs. Data sharing of registries is therefore a unique resource to allow rare dis-
ease research to ﬂourish and any lost data will jeopardize the quality of an already extremely difﬁcult research.
The rules usually applied to research such as the right to withdraw or the need for speciﬁc consent for every
use of data can be detrimental in order to get effective results. Privacy rights regulated through traditional in-
formed consentmechanisms have been regarded as a major barrier in order to effectively share data worldwide.
Some authors argue that this barrier hampers results that could be beneﬁcial to the patients so that another right
will be overstated: the right to quality healthcare. We argue in this paper that privacy has been often interpreted
just one-sided as the right to secrecy but it can entail another meaning: the right to manage one's own private
sphere. Managing it pertains, not only to the right to deny access, but also to the right to grant access. At the
same time research on patient participation and transparency shows that new forms of IT-based informed con-
sent can provide a good balance between the right of individuals to be in control of their data and the opportunity
for science to pursue international research.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The role of genomics in medicine is rapidly and pervasively increas-
ing. Genomics promises many ambitious developments, including per-
sonalized and precision medicine, and tailored drugs. Genomics
knowledge is full of promise for the development of targeted therapies
in rare diseases. In terms of policy, the integration of genomics in health
is pervasive, so much so that the Centers for Disease Control and Pre-
vention (CDC) states that genomics plays a role in nine of the ten lead-
ing causes of death in the United States and that it foresees the
“integration of genomics into pediatric primary care and into public
health practices such as screening programs designed on the basis of
the genetic likelihood to develop certain diseases (Center for Disease
Control and Prevention, 2013)” Genomic research also forms the basis
for precision medicine, and is thus important for our understanding of
rare diseases. Recent advances in genotyping and sequencing have led
to a steep drop in the costs of genome scanning. The introduction of
next-generation sequencing and whole genome sequencing has also
led tomore accurate, precise, and deﬁned procedural outcomes. This ac-
curacy may be used to develop a clinical understanding of what used toascalzoni),
@crb.uu.se (M. Hansson).
. This is an open access article underbe known as general “research results.” Biobank infrastructures are
commonplace in many hospitals, and large research biobanks have
also been created. All these rapid developments in genomics were
made possible by huge international efforts to ﬁnd effectiveways to col-
laborate and share data, samples and technologies. Genomic results are,
in fact, based on collections of data that made genome-wide association
studies possible. Large data collections are necessary in order to ensure
statistical signiﬁcance, and to create international consortia for data
sharing. The European Commission has acknowledged this necessity
by supporting research consortia through substantial grants.
Rare ‘orphan’ disease, or diseases that are either life-threatening or
chronically debilitating, affect a very small percentage of the population.
Rare diseases are challenging subjects of research, in that there are very
few cases upon which researchers may draw conclusions (sometimes
fewer than 100 cases in theworld). In theUnited States, a disease is con-
sidered rare if it is believed to affect fewer than 200,000Americans. Con-
ventional levels of statistical precision are unlikely to be met if a trial is
required to evaluate treatment of a rare disease. In order to obtain a
sample size of statistical signiﬁcance, researchers often use data from
patients in foreign countries. The very existence of rare disease research
requires international collaboration and the movement of samples and
data across national borders. Although genomic research is full of prom-
ise, the need for large data setswill ensure that certain types of genomic
researchwill be difﬁcult to perform. In point of fact, research in rare dis-
ease is extremely difﬁcult due to the limited availability of cases.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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one registry will house the requisite amount of affected persons to sus-
tain a trial. The sharing of data registries is a unique resource that allows
rare disease research to exist. That being said, medical research on
biobanks and registries is only as good as the data it uses; lost data
will jeopardize the quality of an already difﬁcult research endeavor.
To jeopardize genomic research in this way would engender serious
consequences for patients with rare diseases, who would not be able
to beneﬁt from research results. Consequently, the application of certain
research rules (such as the possibility of withdrawal or the need for spe-
ciﬁc consent) to rare disease research can be highly detrimental. This
fact has also been recognized by the European Commission, which re-
quires all member states to have a national research plan for rare dis-
eases in place (Council of Europe, 2009).
The need for extensive data sharing has profound implications for
privacy regulation and for personal data management. The proposed
use of a unique identiﬁer for research in rare disease (i.e., an identiﬁer
code that is applied to subject data and is shared by all researchers
working on that same data) has opened up new questions about secu-
rity, speciﬁcally concerning the chances of re-identiﬁcation born from
cross-matching data from different research centers. The Ofﬁce of
Rare Diseases Research at the National Institute of Health (NIH) has
launched a pilot project to establish theGlobal Rare Disease Patient Reg-
istry andData Repository (GRDR) (NIHOfﬁce of Rare Diseases Research,
2012). The goal of this registry is to establish a data repository for de-
identiﬁed patient data, which will be aggregated using Common Data
Elements (CDEs) and standardized terminology. This data (which will
be available to all investigators) will enable the analysis of many rare
diseases, and will facilitate various biomedical studies (including
clinical trials) to develop drugs and therapeutics, thereby improving
the healthcare and quality of life of many millions of people. De-
identiﬁcation of patient data will also utilize the Global Unique Identi-
ﬁers (GUID) system, which can link patient data to biospecimen data
sets (NIH Ofﬁce of Rare Diseases, 2012).
The protection of personal data has been amajor concern in geno-
mic research. Evolving privacy regulations and existing legal frame-
works have already had an important impact on research and its
future development. Loss of conﬁdential data may negatively affect
participants in research studies. Health data are considered especially
sensitive, and as a result, severe restrictions are imposed on re-
searchers and investigators. E-commerce and banking regulations,
for example, are often applied to research data, the better to create
a safe environment for sensitive data. However, these regulations
end up creating strict and unspeciﬁc privacy rules that, in the con-
text of rare disease, may detrimentally impact the use of the limited
data that is currently available for research. It is therefore critical to
understand the role of privacy as a personal right, and to analyze
privacy in the context of other rights by assessing its impact on
individuals, families and society.
2. Discussion: privacy as a barrier to quality research
Biobanks and medical registries with aggregated clinical data are
vital to the development of higher standards of medical diagnosis and
personalized treatments. The rapid development of pharmacogenomics
underscores the need for these infrastructures as stable libraries for
new and future developments. These infrastructures have been heavily
criticized as constituting a great risk to individual and family genetic
privacy. Privacy has been identiﬁed as “The Issue” around which re-
searchers have assessed the ethical and legal dimensions of data and
sample collection. Privacy has therefore played a dominant role in the
regulation of biobanks and registries, and has been the focus ofmany re-
strictions; as such, privacy has often been conceived of as a barrier to re-
search and development (Mascalzoni et al., 2013; Hansson et al., 2013).
Many countries have enacted regulations that require speciﬁc consent
for the use of data in research. LIBE hopes to change a current EUproposal by introducing an exception that would prohibit secondary
use of existing data without explicit consent (Mascalzoni et al., 2013).
This exception could drastically reduce researchers' reliance on existing
resources, whichwere, in large, collected in the past under the purview
of different regulations. It is well known that re-consent (even when
possible and practical) results in loss of participation — a huge cost to
research efforts.
Privacy has often been regarded as the capacity to identify a person
using his or her own data. The power of genetics to identify research
subjects has played a signiﬁcant role in discussions on privacy. In this
context, privacy entails the protection of a person's identity (and, there-
fore, his or her dignity) in relation to his or her health and genetic data.
This paper considers a broader conception of privacy, as it relates to
individuals and groups in the private sphere. Mainstream interpreta-
tions of privacy (which have been privileged through regulation) regard
privacy as a “secret area,” in which personal data and data-ﬂow tech-
niques are protected to ensure anonymity.
This paper demonstrates that privacy is, indeed, a large concept, and
that even if privacy is heavily associated with secrecy, it entails a
broader area of signiﬁcance that includes the personal sphere and its
management. Not only does privacymanagement imply a negative per-
sonal right to non-interference (such as limiting undesired access and
making personal information secret) but it also implies a positive right
to determine and manage personal information, and to actively have a
say in one's own private sphere (Hansson, 2008).
2.1. Privacy regulations
Soft law provisions, professional codes of conduct and legislation
constitute the normative patchwork that guides scientiﬁc discovery.
Striking a balance can be difﬁcult; moreover, scientiﬁc development
has revealed dilemmas that existing regulations are unable to solve.
The balance between freedomof research and protection of research
participants has been difﬁcult to achieve. In the context of genomic re-
search, privacy is a major issue. Although privacy is recognized as a
human right (Council of Europe, 2006; Unesco 2003), it is important
to acknowledge that privacy is not absolute, and that it needs to be eval-
uated and balanced against constitutional rights.
The Convention on Human Rights and Biomedicine is a European
cornerstone (Council of Europe, 1997a). The aim of this Convention
is the protection of dignity and human rights in relation to biomedi-
cine. The Convention sets forth the norms for the conduct of ethical
and legally-sound research. Article 10 of the Convention states
that: “everyone has the right to respect for private life in relation to
information about his or her health,” and that “everyone is entitled
to know any information collected about his or her health”. Article
5 states that a medical intervention may only be carried out if the
subject gives his or her free and informed consent, and is also given
the right to withdraw his or her consent. Recently, certain authors
have criticized these restrictions (Hansson, 2012) as hampering the
scope of Article 3 of the Convention, which enshrines a right to “eq-
uitable access to health care of appropriate quality.”
Privacy provisions, if applied literally, would severely hamper re-
search efforts and prevent patients from enjoying good-quality stan-
dards of healthcare. Poor-quality diagnostic tests and treatments can
be harmful to patients, and thus can violate the primary medical eth-
ical principle of “do no harm.” In practice, balancing medical beneﬁts
and privacy risks is inherently as well as situationally complex. Qual-
ity is not only a normative requirement in health care, but also a nec-
essary condition for the prevention of harm and for the development
of preventative and diagnostic treatments. Quality assurances have
an intrinsic value in the implementation of the right to health care
(Hansson, 2012). This principle is recognized in Article 12(a) of the
1997 Universal Declaration on the Human Genome and Human Rights,
and underscores the need for shared beneﬁts in research: “[b]eneﬁts
from advances in biology, genetics and medicine, concerning the
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(Article 12),which is “necessary for the progress of knowledge”must be
read together with the duty to “seek to offer relief from suffering and
improve the health of individuals and humankind as a whole.”
Article 1 of the 1997 Declaration also states, “[t]he human genome
underlies the fundamental unity of all members of the human family,
as well as the recognition of their inherent dignity and diversity. In a
symbolic sense, it is the heritage of humanity.” This article supports a vi-
sion of a shared heritage that beneﬁts humankind as a whole.2.2. Right to quality healthcare for rare disease communities
The need to aggregate personal health-related data by linking
patient medical records with clinical registries and biobanks has
become a pressing need in medical research. In order for the collabora-
tive gathering of data on rare diseases to gain statistical signiﬁcance, a
network of clinical registries must be both global and widespread.
As different outcomes are experienced in associationwith diagnosis,
prevention, and treatment, data registries must be continuously up-
dated, the better to follow themedical development of certain diseases.
These data are necessary in order to: (a) predict the future course of dis-
ease; (b) assess the frequency and prevalence of disease across different
populations; (c) assess the outcomeand long-term safety of treatments;
and (d) assess the efﬁcacy of drugs and treatments in order to guide
policymaking and economic decisions relating to prioritization in health
care. Together with human biological samples, medical registries can be
even more useful for attaining these ends. There are direct beneﬁts to
patients from databases and clinical registries, as well as surveys and
questionnaires:
One example should make the case clear: the Human Papilloma Vi-
rus (HPV) vaccine. This vaccine is now available on themarket and is
being included in the organized vaccination programs of many
countries around theworld for the prevention of cervical cancer. De-
velopment of this vaccine would not have been possible without
ﬁrm evidence that the virus is causing the cancer. Prospective stud-
ies that follow exposed subjects until disease diagnosis are an essen-
tial requirement for the inference of causality. Because the cancer
develops several decades after the infection, such studies are not
possible with newly collected samples. However, linkage of national
cancer registries with biobanks identiﬁed stored samples of cervical
cells or serumdating back to the 1960s, and testing such samples for
HPV provided the needed evidence for a causal association. In
Sweden alone, it is estimated that the HPV vaccine will save about
200 lives each year. It can be concluded that vital medical needs
may not be fulﬁlled without the use of registry data and biobanks.
However, the registration and use of medical and personal data as
well as the collection of human tissue samples in biobanks are seen
as controversial, and it is suggested that important competing values
at stakemaywarrant the tradeoff against the intrinsic quality values
they represent.
[(Hansson, 2012, p. 317).]
The updating of personal medical records does not seem to be
problematic in terms of privacy or of patient autonomy; in point of
fact, every medical doctor regards updating patient ﬁles as contrib-
uting to good-quality healthcare. Allowing access to this data by
other healthcare providers in the clinical setting also does not raise
issues for the same reason. Access to medical-quality registries,
research-based registries, biobanks, and, in particular, the linking
of large-database data across national borders is looked upon differ-
ently in the context of research. In terms of good-quality care, there
seems to be no conﬂict between documenting care in medical re-
cords, following-up and conducting long-term assessments through
medical registries and biobanks (whether local or collaborative), andreceiving the best research-based treatments available. However,
access to such resources has been heavily challenged by concerns
for privacy.
Do medical registries and biobanks represent signiﬁcant threats to
individual rights and privacy?
The collection and use of large quantities of health information cre-
ates a substantial challenge for the protection of patient privacy and the
privacy of research subjects (Rothstein and Shoben, 2013a,b). Privacy
security measures (such as coding and de-identiﬁcation) may prove in-
effectual, as re-identiﬁcation is often possible by crosslinking available
databases (Kaye et al., 2012). Loss of informational privacy may lead
to the stigmatization of individuals and communities, such as those
deﬁned by ethnicity, gender, or religion.WendyMariner argues that au-
tonomy and privacy are fundamental interests protected by constitu-
tional law; as such, a constitutional challenge could dismantle vast
numbers of registries that are not based on individual consent. Mariner
recognizes the need to limit intrusions into medical privacy that have
resulted from the wide dissemination of personal medical data. In her
view, even if health research is important, itmust still giveway to inher-
ent principles of law, such as the protection of privacy (Hansson, 2012).
But, as discussed, privacy is not the only right at stake in medical re-
search: access to healthcare and quality of healthcare is also of vital con-
cern. Quality healthcare represents a vital patient and societal interest.
Although quality healthcare may be balanced against privacy concerns,
the following question remains: where should the line be drawn be-
tween these two interests, and is there a way to fulﬁll them both?
2.3. Privacy, autonomy and shared responsibilities
Some authors suggest that in order to achieve better results, sci-
entists should opt for open data-sharing and place less emphasis on
informed consent. It is already possible to bypass the need for in-
formed consent if patient data is unidentiﬁable (Council of Europe,
1997a,b; Tallacchini, 2005). These exceptions tend to reduce tissue
and biological samples to pure information. Forgetting about the
sources of sample data enables a legal shift away from the regulation
of human research to the regulation of data; this technical shift is
embedded with values. Suddenly, it becomes possible to skip certain
procedures; moreover, the “anonymization” of data allows for great-
er freedom to exchange regimes. Identity protection rhetoric misses
the complexity of privacy — as a private sphere that deserves some
degree of control.
Privacy should not be reduced to personal identiﬁcation data
(Council of Europe, 1997b, 2006) but rather should take into account
an “identiﬁcation criterion,” which encompasses the personal dignity
and intimate interests of the individual. This criterion is especially im-
portant in the context of genomic information, as this area impacts
not only individual carriers, but also societal groups.
2.3.1. The private sphere
“The possibility of enjoying a private sphere–informational or
spatial–of one's own is a vital concern in all cultures” (Hansson,
2012). Although there may be some differences of opinions as to the
borders of this sphere, there are certain core elements that transcend
such cultural borders. James Rachels explains why human beings reject
certain types of intrusions by focusing on individual-to-individual rela-
tionships in the social context [24] (Hansson, 2012). According to
Rachels, a private sphere is necessary for human beings to participate
in several different types of relationships. There is, in fact, a close con-
nection between the capacity to maintain different relationships with
different people and the ability to control who may access personal in-
formation. As such, an individual must have access to a private sphere
and must be in control of this sphere. Management of this private
sphere requires that one person decides who may enter this sphere or
have access to private information, and under what conditions. Privacy
is valued as part of social life. An individual's freedom to be left alone or
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context.
2.3.2. Individual vs. inter-subjective responsibility
The fact that an individual has control over third-party access to his
or her own information suggests that privacy is intrinsically related to
autonomy. However, individual autonomy should not necessarily be
seen as a barrier to privacy, as its expression and scope depend on sub-
jective individual, familial and societal contexts.
According to the Council of Europe: “the expression ‘genetic data’
refers to all data, of whatever type, concerning the hereditary char-
acteristics of an individual or concerning the pattern of inheritance
of such characteristics within a related group of individuals. It also
refers to all data on the carrying of any genetic information (genes)
in an individual or genetic line relating to any aspect of health or dis-
ease, whether present as an identiﬁable characteristic or not. The ge-
netic line is the line constituted by genetic similarities resulting from
procreation and shared by two or more individuals” (Council of
Europe, 1997a,b).
In genomic research, focus is never placed on a single individual as
such. Those persons involved in research are particularly valuable as
participants if they form part of a larger group. Genome-wide associa-
tion relies on large numbers and shared characteristics; in research
biobanks, subjects are taken as a whole—either as a community that
shares common characteristics, or as a closer, more extended family,
where any given individual is genetically related to others. Relatedness
among sets of genetic data can help locate characteristics that are
shared by individuals of the same kinship. This fact alone is blurring
the boundary between individuals and genetic communities, and casts
doubts on the feasibility of commonly used ethics tools, such as individ-
ual informed consent and calls for additional forms of participation and
regulation of genomic research. Genetic information concerns not only
individual persons, but also relatives that share the same genetic back-
ground. What we term “privacy risk” is comprised of several aspects,
of which identiﬁcation is only one. This fact raises new questions
about the legitimate uses of such information, and also casts doubts
upon the right to deny possible positive outcomes to a shared heritage.
The fact that genetic information is sharedmeans that it does not belong
to a single individual, and that it is, in away, already beyond the scope of
individual control. For instance, a familymember who provides his own
data is able to infer precise health information about another family
member through the use of statistical tools (Howie et al., 2012). In the
case of genetic counseling, the participation of family members and
the provision of a family history is often helpful (if not necessary) to ar-
rive at a precise diagnosis. Inter-subjective responsibility is thus a seri-
ous issue that must be taken into account.
2.3.3. Providing better chances to vulnerable groups
In the case of vulnerable groups, justice and fair access may pro-
vide a rationale for a speciﬁc regulation, such as those with rare dis-
eases. Orphanet states that: “[t]he ﬁeld of rare disease suffers from a
deﬁcit of medical and scientiﬁc knowledge. For a long time, doctors,
researchers and policy makers were unaware of rare disease and
until very recently there was no real research or public health policy
concerning issues related to the ﬁeld. There is no cure for most rare
diseases, but appropriate treatment and medical care can improve
the quality of life of those affected and extend their life expectancy”
(Orphanet, 2013). When a person is afﬂicted with a rare disease, he
or she is often alone in suffering. The disease is either unlikely to
be diagnosed or is diagnosed late due to lack of knowledge or diag-
nostic tools; as such, patients have fewer chances of obtaining treat-
ment. The rarity of certain diseases is such that the market is too
small to generate commercial interest in drug development; these
diseases are termed “orphan drug” diseases. Rare disease research
should be considered research on vulnerable groups. A patient af-
fected by rare disease is as vulnerable as any other patient withregard to subjective experience of illness, but is actually more vulnera-
ble in terms of healthcare availability and regulations that hamper
healthcare research. Rare disease research only exists thanks to regis-
tries and biobanks, which are often set up by patients themselves
(Genetic Alliance, 2013). If loss of data were to severely hamper re-
search in rare disease, andwere to affect rare disease patients by imped-
ing the proper evolution of care and access to good-quality healthcare,
this could be seen as discrimination against vulnerable groups and as
unjust. Strong societal imbalances necessitate the introduction of afﬁr-
mative action, whichmeans rules that ensure fairness into the develop-
ment of a process so as to seek justice in the output of that process.
One possible conclusion is that individuals should not be given the
choice as to whether or not to have their health records and specimens
used in rare disease research. This interpretation is particularly relevant
for inter-subjective responsibility,where sharing individual information
is the only chance that an individual and others have (whether affected
or not) within a biological family to receive better-quality healthcare.
Does a person have the right to refuse providing his or her data if this
refusal will affect the quality of rare disease research, which may, in
fact, be relevant to both the person's family and society as a whole?
This issue becomes one of public interest if the research data has an
intrinsic value for the quality of healthcare. This fact is of extreme rele-
vance for the translation of genomics into public health policies. In other
words, is there a social duty to overcome individual informed consent in
order to provide justice for a vulnerable group? Are these arguments
strong enough to create an ethical duty to contribute to the develop-
ment of better healthcare, even as against an individual's will to be in-
volved in medical research?2.4. The cost of privacy and the issue of informed consent
It is interesting to observe how the answer to the above questions
may differ according to different cultural frameworks. Risk/beneﬁt
analysis must always take place in a speciﬁc social context. Societal
attitudes towards less regulation are shaped by access to healthcare,
trust in institutions, and the effectiveness of science oversight bod-
ies. In countries where universal healthcare is ensured, the answer
would probably be yes, while in places where citizens place less
trust in the state, and there is less social and health security, the
answer may be no (Hansson, 2012; Kaye et al., 2012; Hansson
et al., 2013; Rothstein and Shoben, 2013b; Mascalzoni et al., 2008;
Oliver et al., 2012).
Data are precious. The right to use and manage data collections is
often conceptualized in terms of ownership, the better to identify
those rights and duties that are speciﬁc to data collection. For instance,
in Material Transfer Agreements (MTAs), the data provider is often
regarded as “the owner,” and ownership of the data, is used as a sum-
mary concept to indicate the set of rights related to a set of data. The
issue of ownership is constantly ﬂowing into the debate on privacy; in
many respects, the right to personally manage one's own data could
be grounded in property theory or as an extension of autonomy. It is
worth considering the meaning of property as relates to data, and why
this meaning holds particular relevance to personal health data privacy.
Data ownership, exchange andproprietary rights (as pertaining to intel-
lectual property) have a great impact on public perception of privacy as
applied to health research. A clear conﬂict exists between the “altruistic
donor” approach at the initial time of participation in research, and
ownership of personal data. The dichotomy between free access to
data (for the advancement of science) as public beneﬁt and the possibil-
ity of using those data for commercial gain would trigger a loss of trust
in the scientiﬁc community (Moore v. Regents University of California,
1990: against the property approach). This tension may affect the rela-
tionship of trust that is required for patient participation in medical re-
search, and may lead to the perception that secrecy and conﬁdentiality
are the only effective measures to be employed against misuse of
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in genomics.
Judith Jarvis Thomson argues that privacy has meaning only to the
extent that it is reducible to property interests (Thomson, 1990). But
property does not always entail full proprietary rights. For instance, a re-
lational approach to property may consider “ownership” rights as not
directly relating to possession, but rather as focused on other consider-
ations, such as the control or power that a subject may have over third-
party access to his or her data. Although a person's data is an object sep-
arated from the body, data subjects may also have a personal interest in
retaining a degree of control over their data in order to avoid harm or to
gain some sort of advantage. This interest is often translated into the
right to grant or deny access to data (Cohen, 2000). This reduces control
to a yes or no response that leaves no room for discussion. Michelman's
vision, which looks at property as a means through which to ensure the
egalitarian distribution of political power and participation, is very in-
teresting in this context (Williams, 1998). According toMichelman's ap-
proach, property can be seen as an “individual's stake” in society
(Michelman, 2012).
This view is especially interesting if it is applied to health research
data. Individual patients may have political or religious objections to
certain research purposes that are made possible through data sharing.
Commercial exploitation of collected data is one such point of conten-
tion. Individuals may notwant their data to be used inways that will af-
fect their identities and private spheres. Theymay notwant their data to
beused in support of political ideas or to dismantle religious beliefs. Cer-
tain individualsmay notwant to contribute to research thatwill identify
markers for “[…] speciﬁc population[s]”, or that will trace the origins of
speciﬁc tribes (as in the Havasupai Case) (Mello andWolf, 2010). Good
oversight structures are necessary to keep these research problems at
bay; however, even theymay be insufﬁcient to contain the implications
of these different concepts.
2.4.1. The cost of consent
As in theWestern legal tradition, the bioethics literature in genomics
generally present individual persons as the subjects of rights (notwith-
standing the fact that the possibility of a balance between individual
rights and community rights may open up new horizons). Informed
consent has been extensively considered in the context of biobank re-
search. The issue of consent comprises a broad spectrum of positions,
ranging from “no consent required” to “speciﬁc consent required at all
times.” A one-size-ﬁts-all approach is very difﬁcult in this context. Al-
though privacy is a primary good that should be protected, it is impor-
tant to acknowledge that there are costs associated with high-quality
diagnosis and treatment.
One argument brought up in the literature is that the right to better
quality healthcare is jeopardized by the need to actively provide speciﬁc
or explicit consent to registries and biobanks (Hansson, 2012). All the
requirements for traditional informed consent (i.e., opting-out, re-
consent, etc.) imply that registries will be affected both by those ele-
ments that are included or omitted. This issue leads to incomplete infor-
mation bias that affects research outcomes. Even though consent-bias
may be relatively small in the context of large clinical trials or of popu-
lation biobanks, the same cannot be said of rare disease registries and
rare disease biobanks, for which even the slightest perception of bias
can have a severe impact, in light of the scarcity of materials and infor-
mation available for research. Some authors suggest that this bias leads
to a societal obligation to participate in research for the public good
(Francis and Francis, 2013); if the right to privacywereweighed against
the right to better healthcare, the latter should prevail.
In contrast, Mark Rothstein asserts that the degree of consent bias
caused by informed consent has been overstated; that statistical tech-
niques can mitigate this bias; and that a low level of imprecision is an
acceptable social cost for conducting ethically-responsible research
(Rothstein and Shoben, 2013a,b). Supporting Giesbergtz's position,
Rothstein also suggests that new forms of consent should beimplemented for research that have a special social or “public good”
value (excluding highly sensitive research) (Giesbertz et al., 2013). In
such cases, the author suggests a thick opt out procedure that will pro-
vide for higher-than-normal participation and will simultaneously ac-
knowledge the rights of individuals to make decisions in respect of
their own private spheres. In a thick opt out procedure, patients should
be well informed about research but they should not actively agree to
participate. In fact, the default position would be agreement to be into
research and patients who do not want to participate could actively dis-
agree by opting out. The fact that opt out options do not affect research
is supported by the report of a Swedish study revealing that, even with
an especially elaborate system for opting out of consent (where detailed
information and consent forms were offered at sampling that patients
could take home and ﬁll in), only 1 in 19,000 actually did opt out
(Johnsson et al., 2008). Recent legislation in Finland also supports this
view, and foresees the implementation of opt out options for registries
and biobanks.
Although both positions give rise to interesting arguments, this
paper's conclusions may also be driven by other considerations.
Open consent is always grounded in a risk/beneﬁt assessmentwhere
there is a low risk associated with database research. However, even
research on bio-specimens can be reduced to pure information. This
paper has suggested that risks associated with the dissemination of
data are very much socially and culturally situated; in certain coun-
tries, for example, individuals may not want their data to be freely
shared for the purposes of research.
Identiﬁcation and stigmatization are also issues. It is not ethically
acceptable for an individual to provide data for the public good, and
then for that individual to be left unprotected in the public sphere.
Some authors may argue that democratic societies should ensure
trustful governance and the implementation of effective oversight
mechanisms. But in a “world sharing setting,” societies are unable
to guarantee that such democratic assumptions will be met, or that
codiﬁed or de-identiﬁed data will not lead to any harm. De-
identiﬁcation has been proven insecure (McGuire and Gibbs, 2006;
Kaye, 2012).
But even if such research were devoid of risk (either discrimina-
tory, access, or informational), would individuals be keen on giving
up their right to a speciﬁc or explicit consent? Control over consent
has, as suggested, the political power to acknowledge or deny trust
to a particular institution. At the same time, consent can also lead
to better and more ethically-grounded and supported research ef-
forts. A well-organized consent process for prospective studies
may, in fact, have a very positive impact on patient participation,
and transform reluctant patients into supporters.
3. Results of the discussion: patients as partners and the option of
dynamic consent
An analysis of the costs associated with consent should also in-
clude an examination of the costs of “no consent” for the use of sam-
ples and information. Several studies demonstrate that research
participants across a range of populations and disease groups wish
to be informed if wide data-sharing procedures are implemented
(Tabor et al., 2011). In their paper, McGuire et al. clearly show that
patients would feel deceived and angry if they found out that their
data was shared without their knowledge and consent; this scenario
would occur even where patients would have gladly shared their
data if they had been asked to do so or had been adequately informed
(Oliver et al., 2012). Tabor et al. presented a study in which 70% of
participants felt that notiﬁcation of deposit of data in DBGap after
the fact, that is, without prior notiﬁcation, would be unacceptable.
Thus, transparency seems to play a great role in maintaining the
trust of individuals that are included in registries and biobanks.
In order to improve researcher–patient relationships, researchers
should consider patients as partners in research and acknowledge
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namic consent in Rome, Sharon Terry (Director of Genetic Alliance)
told the audience about how she and her husband did not want
their children, who were affected by a rare disease, to be involved
with researchers whom they did not trust. They believed that re-
searchers at that time were headed in the wrong direction, and
that these researchers should not be trusted with their children's
samples and data, since this research could potentially have an im-
measurable impact on the lives of their children. The only political
power that Terry and her husband had at that moment to object to
this research policy was their ability to say “no”—a vote against this
research. Following this experience, Terry and her husband built up
relationships with other parents in what has now become a huge en-
terprise in support of research led by patients for patients. Genetic
Alliance is now the world's leading nonproﬁt health advocacy orga-
nization committed to transforming health through genetics and
promoting an environment of openness centered on the health of in-
dividuals, families, and communities. Genetic Alliance's network in-
cludes today more than 1200 disease-speciﬁc advocacy
organizations, as well as thousands of universities, private compa-
nies, government agencies, and public policy organizations. Patients
understand that research is in their best interests, and that research
should be performed in themost effective way possible. An acknowl-
edgment of this interest is important in order to build a relationship
based on mutual trust.
Sustainable data quality requires long-term commitment. This
commitment requires that new forms of patient participation be in-
cluded in research policy-building, so that patients become active
partners in research rather than passive providers of information. Al-
though new technologies create additional privacy concerns, they
can also assist in solving a number of patient concerns. A number
of participant centric interfaces (PCI) have been developed to allow
dynamic consent procedures (Kaye et al., 2012). A dynamic informed
consent model is accessible online and provides ﬂexible options (re-
turn of results options, donation of samples and data to research etc.)
that can be changed over time. “This interface enable patients to
change preferences over time and have their choice revoked when
appropriate, to track and audit any changes made, and to choose
when and how they are contacted” (Kaye et al., 2012). By enabling
patients and research participants to determine the degree to
which theymay exercise control over personal information and sam-
ples over time, dynamic consent aims to place patients and research
participants at the center of decision-making.
It is, in fact, possible to manage howmuch information is desired as
well as to allow for choice in terms of the level of participation and com-
munication up front. This approach also constitutes a perfect tool for a
thick opt out procedure.
Special options, such as the donation of data for research in the event
that a patient becomes incapacitated or dies, are ethically acceptable,
provided that individuals have a genuine chance to change their options
over time. The use of PCIs ensures compliance with legal requirements,
as options in such cases can be easily updated. PCIs also ensure that an
open channel of communication is created between patients and re-
search centers. This form of electronic consent is in noway burdensome
for research; updates can be easily communicated to patients, who are
given the opportunity to transparently inform and manage their
participation.
The capacity to trust in research is very precious, especially in the
light of the high-quality data needed for prospective studies in rare
disease. The inclusion of family members in high-quality studies
calls for trust, and requires that patients be re-contacted over time
for the collection of data. If active consent resulted in an unsustain-
able cost for rare disease research, an opt-out procedure would be
rendered unaffordable. Very few rare disease patients (if any)
would withdraw from a study if they were truly informed about its
importance. That being said, patients should be allowed to withdrawif they have strong reasons for doing so. In such cases, the scientiﬁc
community may be made aware of additional problems and in this
particular research setting, some alternative frameworks have been
proposed (Kaye et al., 2012).
Consent for research in rare disease concerns two distinctive
areas: the use of data registries and the use of biosamples. Patients
are aware of the kinds of information that are contained in registries,
as they have already been diagnosed in order to be in the registry. In
such cases, the patient controls the type of information provided.
New bio-sample collections may beneﬁt from an opt-out strategy
(Giesbertz et al., 2013). A thick opt out procedure foresees the imple-
mentation of an information strategy that will enable patients to
make real choices. Such procedures should produce higher participa-
tion rates while afﬁrming individual rights and autonomous choices.
This option could be also implemented for existing collections if it
was supplemented with a communication campaign, which would
make patients aware of the uses to which their samples and data were
being put. That being said, it is difﬁcult to delineate just how thick an
opt out procedure should be.
New collections of bio-samples and new registries that are usual-
ly linked together can also be used for extensive genetic studies;
these studies may include whole genome scans and exon sequenc-
ing. These kinds of analyses are sensitive; a new ethical framework
is needed (Bledsoe et al., 2013). Issues associated with these kinds
of analyses, such as return of results, require the attention of partic-
ipants. The need to re-contact patients calls for something different
than traditional consent, and would be best served (from a patient
and scientiﬁc perspective) by a dynamic consent model.4. Conclusions
Genomics is rapidly changing over time. This ongoing evolution
requires further changes in policy research. Traditional speciﬁc indi-
vidual informed consent is neither possible nor desirable in order to
attain a quality standard of care for patients with rare diseases. How-
ever, new forms of consent will allow for compliance and ensure that
patients are both respected and acknowledged for their role in re-
search. In this way, researchers will promote participant trust and
respect for participant autonomy. For medical registries and existing
specimen collection biobanks, a thick opt-out strategy may be sufﬁ-
cient (in lieu of an opt-in consent strategy) to acknowledge respect
for patients. Information may be accessible through the web and
via posters and leaﬂets in hospitals, including information about
coding and safety standards for data and samples; such information
will maintain high-quality diagnoses, treatments, follow-up, and
medical research endeavors.
Dynamic consent models are recommended for prospective col-
lections. Trust in research is very precious, especially in light of the
high-quality data that is needed for prospective studies in rare dis-
ease. The inclusion of family members in high quality studies not
only calls for trust, but also for the need to re-contact patients
over time for the further collection of data or for return of results
(Green et al., 2013). If active consent results in an unsustainable
cost for rare disease research, new technologies and new forms of
consent can provide compliance standards, while still respecting
the integrity of the private sphere. Patients understand and support
science if they are truly informed. If patients have strong reasons
that lead them to withdraw from rare disease research, then they
should be allowed to do so. The scientiﬁc community may in such
a case learn what the problem was.
Transparency, patient participation in policy-building, and socie-
tal control can also help to preserve respect for autonomy within a
reasonable account of the notion of privacy, regarded as a vital
good to be attained and protected within the wider framework of
social participation.
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